Table 1.
Patient’s characteristics (n = 57)
| Variable | |
|---|---|
| Age (ys) | 51.0 ± 9.8 |
| Gender, n(%) | |
| Male | 50 (87.7) |
| Female | 7 (12.3) |
| BMI (Kg/m2) | 25.7 ± 3.6 |
| Level of instruction (ys) | 10.8 ± 3.1 |
| History of HIV infection (ys) | 11.1 ± 7.5 |
| Risk factors, n(%) | |
| MSM | 22 (38.6) |
| Ex-IDU | 11 (19.1) |
| Heterosexual | 24 (42.1) |
| Therapy, n(%) | |
| NRTI | 53 (93.0) |
| NNRTI | 20 (35.1) |
| IP | 20 (35.1) |
| INSTIs | 20 (35.1) |
| HCV, n(%) | 9 (15.8) |
| HBV, n(%) | 6 (10.5) |
| Glycaemia (mg/dl) | 98.8 ± 48.8 |
| Total cholesterol (mg/dl) | 198.2 ± 44.2 |
| HDL cholesterol (mg/dl) | 51.8 ± 16.9 |
| LDL cholesterol (mg/dl) | 113.4 ± 40.0 |
| Triglycerides (mg/dl) | 164.8 ± 99.0 |
| Creatinine (mg/dl) | 1.0 ± 0.9 |
| Albumin (g/dl) | 4.6 ± 1.0 |
| 25-0H D Vitamin (ng/ml) | 26.8 ± 9.3 |
| Homocysteine (μmol/l) | 15.1 ± 6.3 |
| B12 Vitamin (ng/ml) | 378.5 ± 151.8 |
| Folate (ng/ml) | 9.8 ± 13.7 |
MSM men sex with men; IDU injection drug users; NRTI nucleoside reverse transcriptase inhibitor; NNRTI non-nucleoside reverse transcriptase inhibitor; IP Protease Inhibitors; INSTIs Integrase strand transfer inhibitors